Altimmune, Inc

Contributing Author

Recent Articles by Altimmune, Inc

Oct-20	Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting 2025 ALT GlobeNewswire
Sep-29	Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide ALT GlobeNewswire
Sep-23	Altimmune to Participate in Two Upcoming Investor Conferences ALT GlobeNewswire
Sep-15	Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer ALT GlobeNewswire
Aug-26	Altimmune to Participate in Upcoming Investor Conferences ALT GlobeNewswire
Aug-19	Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD) ALT GlobeNewswire
Aug-12	Altimmune Announces Second Quarter 2025 Financial Results and Business Update ALT GlobeNewswire
Aug-11	Altimmune Board of Directors Appoints Jerry Durso as Chairman ALT GlobeNewswire
Aug-05	Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025 ALT GlobeNewswire
Jul-09	Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD) ALT GlobeNewswire
Jun-26	Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH ALT GlobeNewswire
Jun-25	Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26 ALT GlobeNewswire
Jun-13	Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association's Scientific Sessions ALT GlobeNewswire
May-19	Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD) ALT GlobeNewswire
May-14	Altimmune to Participate at Two Upcoming Investor Conferences ALT GlobeNewswire
May-13	Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital ALT GlobeNewswire
May-13	Altimmune Announces First Quarter 2025 Financial Results and Business Update ALT GlobeNewswire
May-08	Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress ALT GlobeNewswire
May-06	Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025 ALT GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.